Document is current
Any future updates will be listed below
-
Authors
Sinclair, Rodney
Mesinkovska, Natasha
Mitra, Debanjali
Wajsbrot, Dalia
Law, Ernest H.
Wolk, Robert
King, Brett
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03732807 at ClinicalTrials.govDocuments that mention this clinical trial
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
https://doi.org/10.1007/s40257-024-00899-4
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
https://doi.org/10.1007/s13555-024-01260-7
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 25 September 2024
First Online: 23 October 2024
Declarations
:
: This study was funded by Pfizer Inc. The sponsor, Pfizer Inc, was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript for publication. Medical writing and editorial support provided by Nucleus Global were funded by Pfizer Inc.
: R.S. reports professional services for AbbVie, Acrotech, Amgen, Arena, Arcutis, Aksebio, AstraZeneca, Ascend, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Cutanea, Connect, Demira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, MedImmune, Merck, MSD, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone, Roche, Sanofi, Samson Clinical, SUN Pharma, and UCB. N.M. reports professional services for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly, La Roche-Posay, and Pfizer. D.M., D.W., E.H.L., and R.W. are employees of or hold stock or stock options in Pfizer Inc. B.K. has received honoraria and/or consultation fees from AbbVie, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He has previously served on speaker bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See for more information.
: This study was approved by the institutional review boards or ethics committees of the participating institutions. The study was conducted in accordance with the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and the Declaration of Helsinki.
: Written informed consent was obtained from each patient, parent, or the patient’s legal representative.
: Not applicable.
: Not applicable.
: E.H.L. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript. Conceptualization: D.M., D.W., E.H.L., R.W. Data curation: R.S., N.M., D.M., D.W., E.H.L, R.W., B.K. Writing—original draft: E.H.L. Writing—review and editing: R.S., N.M., D.M., D.W., E.H.L., R.W., B.K. Formal analysis: D.W.
